Daily Intelligence for Biotech Investors

The deal tapeserious biotech investors actually read

Top news, M&A, BD&L, IPOs, and VC financings — distilled to a 5-minute read every market morning. No hype. No filler. Just the signal.

Trusted by 2,000+ biotech execs, VCs, BD leads, public market investors - free

Latest Editions

Daily

Aug 17

Monday: AstraZeneca's 895-patient bispecific bet folds

Capricor doubles on an FDA reprieve, and Redx backs into Nasdaq with $125M.

Aug 14

Friday: BMS lands the first CELMoD at $29,500 a cycle

Zipalertinib clears Phase 3, and the FDA puts a price on where you run Phase 1.

Aug 13

Thursday: Definium's LSD pill goes 2-for-2 in Phase 3

Plus: PTC raids the Sangamo estate for $111M, and Vykat XR draws heat.

Aug 12

Wednesday: Zydus options a $475M shot at alpha-1

Three drugmakers take Illinois to court, and crossover money backs an FSHD editor.

Aug 11

Tuesday: Jazz pays $820M upfront for Actio

Jazz swings for rare epilepsy, Trump targets childhood shots, and Sionna hands Vertex a free pass.

2,000+

Subscribers

5×

Issues per week

16+

Research reports

~$188.9B

M&A tracked YTD

Research Hub

Live trackers & research

Live Trackers

Biotech M&A Tracker 2026

Every control transaction in 2026 — target, acquirer, deal value, premium-to-unaffected, and investor-grade rationale. 66 deals. ~$188.9B tracked.

Last updated 13 August 2026

Biotech BD&L Tracker 2026

Licensing and partnering deals — upfronts, milestones, royalties, territory rights, and a one-line why it matters. 119 deals. Up to US$18.5B largest package.

Last updated 13 August 2026

Biotech IPO Tracker 2026

Every biotech IPO this year — pricing date, proceeds, valuation at pricing, and aftermarket performance. 21 deals. ~$6.5B tracked.

Last updated 13 August 2026

Biotech Venture Funding Tracker 2026

VC and crossover rounds — company, stage, lead investors, therapeutic area, and what they are building. 145 deals. US$2.1B largest round.

Last updated 13 August 2026

Research

Most Active Biotech Investors 2026

Ranked league table of the most active biotech and biopharma investors in 2026 by qualifying deal participation.

Biotech Conference Calendar 2026

Major biotech and biopharma conferences in 2026 across the US, UK, and EU, including investor events, scientific catalysts, and partnering meetings.

Top 10 BioPharma M&A Deals of 2025

Ranked list of the 10 biggest biopharma and biotech acquisitions announced in 2025, with stage, therapeutic area, and investor-grade read-through.

Biotech M&A H1 2026 Report

49 deals, ~$149B in value. Q2 nearly doubled Q1. Five $10B+ takeouts, all in Q2. Lilly signed 11 deals.

Biotech M&A Q1 2026 Report

16 deals, $44B in value, and what the deal tape signals about where strategic buyers are paying up.

2024 Biopharma M&A: Every $1B+ Deal

The complete list of 2024 biopharma acquisitions worth $1B or more — public and private targets.

Biotech Funding Terms Glossary

Plain-English definitions of the deal terms that appear in press releases, term sheets, IPOs, and M&A announcements.

About BioBucks

BioBucks is a daily newsletter for biotech and biopharma investors — covering M&A, BD&L deals, IPOs, venture rounds, and catalyst-driven market moves, with the framing that institutional dealmakers actually care about.

Every edition is written to be read in under 5 minutes, with the why it matters front and centre. No press release regurgitation. No noise.

Alongside the daily tape, the Research Hub provides live trackers and standalone reports that serve as reference tools for the community.

Who reads BioBucks

VC / GrowthBiotech venture investors tracking the deal environment

BD&LBusiness development professionals monitoring partnerships

Public MarketsBuyside analysts and portfolio managers

FoundersBiotech CEOs watching comps and M&A premiums